Xvivo Perfusion
515 SEK -0,58%2 investorer følger denne virksomhed
Xvivo Perfusion is a medical technology company. The company provides solutions for lung transplantation. Examples of products that the company delivers include needles, organ storage, and cooling solutions. The products are resold to clinics and research institutes around the global market, with the largest business presence in the Nordics and Europe. The company was established via a spin-off from Vitrolife in 2012 and is headquartered in Gothenburg.
Omsætning
-
EBIT %
-
P/E
167,75
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
XVIVO
Daglig lav / høj pris
511 / 523
SEK
Markedsværdi
16,22 mia. SEK
Aktieomsætning
9,12 mio. SEK
Volumen
18 t
Seneste videoer
Finanskalender
Delårsrapport
24.10.2024
Årsrapport
28.01.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Bure Equity | 14,3 % | 14,3 % |
Fjärde AP-fonden | 9,0 % | 9,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
![XVIVO, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/32e3d21b-04e6-451a-86ef-6765d2c9dea8.png)
XVIVO, Audiocast with teleconference, Q2'24
Interim report January – June 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q2 2024
Conference call on Interim Report
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
Redeye: XVIVO Q1 - Back on track
![XVIVO, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ede0024e-8729-4786-908b-04a27ca63617.png)
XVIVO, Audiocast with teleconference, Q1, 2024
Interim report January-March 2024
Modular Finance IR Consensus: Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Results from XVIVO’s clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague
Conference call on Interim Report
Annual Report 2023
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)
The first-ever transplantation with a donor heart transported across the Atlantic Ocean – made possible by the use of XVIVO’s heart technology
Redeye: XVIVO - Stepping up the pace during 2024
![XVIVO, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/435ce1b3-b864-4027-a86d-23745eb4cd87.png)